Business Description
Aclaris Therapeutics Inc
NAICS : 541714
SIC : 8731
ISIN : US00461U1051
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 279.59 | |||||
Equity-to-Asset | 0.8 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.95 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 43.4 | |||||
3-Year EBITDA Growth Rate | -14.3 | |||||
3-Year EPS without NRI Growth Rate | -10.4 | |||||
3-Year FCF Growth Rate | -7.5 | |||||
3-Year Book Growth Rate | 38.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.64 | |||||
9-Day RSI | 37.58 | |||||
14-Day RSI | 42.63 | |||||
6-1 Month Momentum % | -75.5 | |||||
12-1 Month Momentum % | -86.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.16 | |||||
Quick Ratio | 4.16 | |||||
Cash Ratio | 3.85 | |||||
Days Sales Outstanding | 5.24 | |||||
Days Payable | 195.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.3 | |||||
Shareholder Yield % | 0.33 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 42.14 | |||||
Operating Margin % | -372.22 | |||||
Net Margin % | -283.15 | |||||
FCF Margin % | -254.84 | |||||
ROE % | -50.99 | |||||
ROA % | -38.95 | |||||
ROIC % | -157.55 | |||||
ROC (Joel Greenblatt) % | -7366.31 | |||||
ROCE % | -57.33 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.64 | |||||
PB Ratio | 0.53 | |||||
Price-to-Tangible-Book | 0.53 | |||||
EV-to-EBIT | 0.3 | |||||
EV-to-EBITDA | 0.31 | |||||
EV-to-Revenue | -1.13 | |||||
EV-to-FCF | 0.44 | |||||
Price-to-Net-Current-Asset-Value | 0.93 | |||||
Price-to-Net-Cash | 1.05 | |||||
Earnings Yield (Greenblatt) % | 333.33 | |||||
FCF Yield % | -95.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Ā
Total Annual Return % Ā
Aclaris Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 31.249 | ||
EPS (TTM) ($) | -1.27 | ||
Beta | -0.64 | ||
Volatility % | 99.1 | ||
14-Day RSI | 42.63 | ||
14-Day ATR ($) | 0.043396 | ||
20-Day SMA ($) | 1.239325 | ||
12-1 Month Momentum % | -86.84 | ||
52-Week Range ($) | 0.6052 - 10.87 | ||
Shares Outstanding (Mil) | 71.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aclaris Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aclaris Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aclaris Therapeutics Inc Frequently Asked Questions
What is Aclaris Therapeutics Inc(LTS:0H8T)'s stock price today?
When is next earnings date of Aclaris Therapeutics Inc(LTS:0H8T)?
Does Aclaris Therapeutics Inc(LTS:0H8T) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |